PocketView ECG software is a version of Cardioview™ 3000 software, a Windows-based program intended to interpret electrocardiograms. PocketView ECG software receives, displays and stores a single or standard 12 Lead Simultaneous ECG recording using a proprietary digital data transmission protocol. The device contains proprietary software algorithms to receive, store, and interpret the ECG signal. PocketView ECG Software allows the ECG information to be displayed on a commercially available personal digital assistant (PDA) running the Windows CE operating software.

Device Description

The proposed device is modification to the Cardioview™ 3000 software that allows the 12 Lead Simultaneous Cable to be linked to commercially available personal digital assistants (PDA) running the Windows CE operating system.

AI/ML Overview

The provided text describes a 510(k) submission for the "PocketView ECG software," which is a modification of the "Cardioview™ 3000 software." The key modification is the ability to display ECG information on commercially available personal digital assistants (PDAs) running Windows CE.

Based on the provided text, the following information can be extracted:

Table of Acceptance Criteria and Reported Device Performance: This information is not explicitly detailed in the provided text. The document states, "Nonclinical testing was performed to evaluate the modification to the predicate device. Testing verified that the modified device displayed acceptable performance." However, specific criteria (e.g., accuracy percentages, error rates) or how "acceptable performance" was quantified are not provided.
Sample Size Used for the Test Set and Data Provenance: This information is not provided in the text. The document only mentions "Nonclinical testing was performed."
Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts: This information is not provided in the text.
Adjudication Method for the Test Set: This information is not provided in the text.
Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study: An MRMC study is not mentioned. The focus of this 510(k) is the display capability on a PDA, not an AI interpretation improvement.
Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study: The document indicates that the device "contains proprietary software algorithms to receive, store, analyze, and interpret the ECG signal." This implies a standalone algorithm for interpretation. However, specific standalone performance metrics or a dedicated standalone study are not detailed in this submission. The "nonclinical testing" was performed to evaluate the modification (PDA display), not necessarily to re-evaluate the core interpretation algorithm's standalone performance, which is presumably a characteristic inherited from the predicate device.
Type of Ground Truth Used: This information is not explicitly provided. Since it's an ECG interpretation device, the ground truth would typically be established by expert cardiologists.
Sample Size for the Training Set: This information is not provided in the text.
How the Ground Truth for the Training Set Was Established: This information is not provided in the text.

In summary, the provided 510(k) submission focuses on the substantial equivalence of adding PDA display functionality to an existing ECG interpretation software. It does not detail specific performance studies, acceptance criteria, or ground truth methodologies for the interpretation algorithms themselves, as these would have been established for the predicate device. The "nonclinical testing" mentioned primarily verified the acceptable performance of the modification (PDA connectivity and display).

Summary

{0}------------------------------------------------

KO13311

510(k) SUMMARY

Submitted by:

JAN 0 3 2002

Micromedical Industries Ltd

Date Prepared:

October 1, 2000

Proposed Device:

PocketView version of Cardioview™ 3000 software

Predicate Device:

Cardioview™ 3000 software

Device Description:

Statement of Intended Use:

Summary of Technological Characteristics or New Device to Predicate Devices

The technological features of PocketView ECG do not differ significantly from Cardioview™™ 3000 software. The predicate device and the modified device are identical with the exception that the modified device has the connectivity feature allowing the ECG information to be displayed on a commercially available personal digital assistant (PDA) running Windows CE operating system.

CONFIDENTIAL

{1}------------------------------------------------

Discussion of Nonclinical Tests; Conclusions Drawn from Nonclinical Tests

Nonclinical testing was performed to evaluate the modification to the predicate device. Testing verified that the modified device displayed acceptable performance.

CONFIDENTIAL

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three abstract shapes that resemble a person with outstretched arms, symbolizing care and protection.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JAN 0 3 2002

Mr. Stephen Cresswell MicroMedical Industries, Ltd. 11 Technology Drive Labrador, Queensland AUSTRALIA

Re: K013311

Trade Name: PocketView ECG Software Regulation Number: 21 CFR 870.1025 Regulation Name: Patient Physiological Monitor Regulatory Class: Class III (three) Product Code: MHX Dated: November 12, 2001 Received: December 4, 2001

Dear Mr. Cresswell:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{3}------------------------------------------------

Page 2 - Mr. Stephen Cresswell

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Odile Tel

Bram D. Zuckerman, M.D. Acting Director Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Indication for Use

510(k) Number: K013311

PocketView ECG Software Device Name:

Indication for Use:

PocketView ECG software is a version of Cardioview™ 3000 software, a Windows-based Pocket VIEW DOO soltware is a version di Station and personal digital assistant (PDA). program micindod to merprovers displays and stores a single or standard 12 Lead Focker FCG sontware roost to, is transmitted either locally or transtelephonically using a proprietary digital data transmission protocol. The device contains proprietary software algorithms to receive, store, analyze, and interpret the ECG signal.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

Over-The-Counter Use __ OR

Regulation Number and Section

§ 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm).

(a)
Identification. The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.(b)
Classification. Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.